Solix Technologies and Symbiosis Center Announce Center of Excellence for Drug Development
Santa Clara, CA & Pune, India – March 18, 2026 – Solix Technologies, a global leader in enterprise data management and Enterprise AI, announced a Memorandum of Understanding (MoU) with Symbiosis Center for Entrepreneurship & Innovation (SCE) in collaboration with Symbiosis Medical College for Women (SMCW) to establish a Center of Excellence (CoE) in New Drug Development and Drug Repurposing. The announcement was made during TAL HealthFest 2026.The Center of Excellence will integrate computational intelligence and AI-driven in-silico modeling with molecular validation frameworks and in-vivo translational research. Initial focus areas will include Alzheimer’s disease and Priority Antimicrobial Resistant (PAMR) pathogens.
“At Solix, we believe the future of drug discovery lies in intelligent data harmonization and AI-driven translational science,” said Mr. Sai Gundavelli, Founder & CEO, Solix Technologies. “By partnering with Symbiosis Medical College for Women, we are creating a platform that integrates computational intelligence with molecular and clinical validation.”
Dr. Sapttarishi (Tony) Ghosh, CEO - SCEI, Symbiosis International University, added, “This collaboration strengthens our mission to empower women in medicine and advance translational healthcare research.”
The Center of Excellence aims to identify and validate novel therapeutic targets, develop CNS-active and antimicrobial lead molecules, repurpose approved and investigational drugs, enable industry collaboration and CRO services, support intellectual property generation and train scholars in translational drug development.
Mr. Murali Krishnam, VP - Pharma AI Product Strategy, Solix Technologies, stated that the initiative will help bridge gaps across diverse data domains, enabling organizations to unlock unified insights and accelerate discovery.
TechNVision Ventures Limited is a pioneer in creating next-generation enterprise software businesses. Solix Technologies Inc. is an affiliate of TechNVision Ventures Limited.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.